Clinical Outcomes in Patients Switched from Adalimumab to Baricitinib Due to Non-Response and/or Study Design: Phase III Data in Patients with Rheumatoid Arthritis
Ann Rheum Dis. 2019 Jul;78(7):890-898.
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Ann Rheum Dis. 2019 Jul;78(7):890-898.
J Clin Pharm Ther. 2019 Jun;44(3):384-396.
ADV Ther 2018; 35(10):1525–63 DOI: 10.1007/s12325-018-0757-2
Arthritis Care Res (Hoboken) 2019 Jan;71(1):71-79. DOI: 10.1002/acr.23585
Please click the links below to go to the CSF review of each paper.
N Engl J Med 2017; 377:1537-50. DOI: 10.1056/NEJMoa1615975
RMD Open. 2017; 3(2): e000546. doi: 10.1136/rmdopen-2017-000546
RMD Open;3:e000496. doi: 10.1136/rmdopen-2017-000496
Arthritis Rheumatol 2014;66:2675–84
Ann Rheum Dis 2017;76(11):1853-1861. doi: 10.1136/annrheumdis-2017-211259